Azenta (AZTA) AI Stock Analysis

• Market Cap: $1.24B
• Dividend Yield: N/A
• Average Volume (3M): 798.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.91
• Revenue Growth: -9.49%
• EPS Growth: 58.97%
• Country: US
• Employees: 3,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.09
• Shares Outstanding: 46,061,527
• 10 Day Avg. Volume: 586,029
• 30 Day Avg. Volume: 798,725
• PEG Ratio: 0.39
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 2.21
• P/FCF Ratio: 34.28
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 1.70
• Enterprise Value/Gross Profit: 3.76
• Enterprise Value/Ebitda: 18.78
• 1Y Price Target: $40.25
• Price Target Upside: 42.83% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): 0.79
• Revenue Forecast (FY): $617.70M

• Rating: 55 Neutral
• Price Target: $29.00 ▲(2.91% Upside)
• Action: Reiterated Date: 02/05/26
• Date: Action: Reiterated 02/05/26

AZTA’s score is driven primarily by solid financial stability (low leverage and currently positive cash flow) and reaffirmed guidance supporting a margin-improvement narrative. These positives are weighed down by a very weak technical setup (stock below all major moving averages with bearish momentum) and ongoing profitability challenges, with near-term margin pressure highlighted on the earnings call.

Positive Factors

Very strong balance sheet / low leverage

Azenta's extremely low leverage and large equity base provide durable financial flexibility. With virtually no debt, the company can fund capex, M&A, and the $250M repurchase program without stressing liquidity, making capital allocation and downside resiliency structural advantages.

High liquidity & positive free cash flow

Material cash reserves and current positive free cash flow give Azenta multi-quarter optionality to invest in automation, regional expansion, or return capital. Although FCF has been uneven historically, the present cash position supports operations and strategic initiatives over the next several quarters.

Attractive underlying margins and diversified services

Healthy gross margins and a diversified mix (sample management, genomics, Multiomics, biorepositories) point to durable unit economics. Recurring storage and genomics services create predictable demand and allow operational leverage as volumes recover, underpinning sustainable margin improvement.

Negative Factors

Persistent operating losses

Despite revenue recovery and gross margin strength, ongoing negative EBIT and net losses limit return generation and make the investment thesis execution-dependent. Continued losses constrain reinvestment capacity and require sustained margin improvement to deliver consistent profitability.

Significant recent gross margin compression

A 360bp drop in gross margin driven by underutilized lab capacity, regional mix shifts and rework underscores operational sensitivity. Margin compression reduces cash conversion and highlights execution risk in automation and capacity utilization until volumes normalize or productivity initiatives scale.

Lumpy revenue cadence & end-market headwinds

Management's characterization of a transitional year with timing-driven bookings, North American softness and Sanger sequencing declines implies ongoing demand variability. This makes forecasting, capacity planning and margin recovery dependent on a back-half rebound, increasing execution and timing risk.

Azenta Business Overview & Revenue Model

Company Description

Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.

How the Company Makes Money

Azenta generates revenue through multiple streams, primarily from its biobanking and genomic services. The company charges clients for sample storage, management, and processing, which are essential for research and clinical trials. Additionally, Azenta offers genomic analysis services, including sequencing and data interpretation, which are crucial for clients engaged in genetic research and diagnostics. Significant partnerships with pharmaceutical companies, research institutions, and academic organizations enhance its revenue generation, as these collaborations often lead to long-term contracts and increased service utilization. Furthermore, Azenta's expansion into international markets and investment in cutting-edge technologies contribute to its growth and profitability.

Azenta Financial Statement Overview

Summary

Well-capitalized balance sheet is a major strength (very low leverage), and cash flow is currently positive with positive free cash flow. However, profitability remains weak with negative EBIT/net income and historically volatile results, keeping the overall financial profile in a “prove-it” phase.

Income Statement

AZTA shows improving top-line momentum in TTM (Trailing-Twelve-Months), with revenue up 19.1% and a solid gross margin (~46%), indicating good underlying product/service economics. However, profitability remains pressured: EBIT and net income are still negative (net margin about -10%), and results have been volatile over the last few years (including a much deeper loss in 2024). Overall, the revenue rebound and healthy gross margin are positives, but the continued operating losses and inconsistency keep the score below average.

Balance Sheet

The balance sheet is a clear strength. Leverage is very low (debt-to-equity around 0.03 in both the latest annual period and TTM), supported by a large equity base relative to assets. The main weakness is that returns remain negative due to ongoing net losses (negative return on equity), but from a solvency and financial flexibility standpoint, AZTA appears well-positioned.

Cash Flow

Cash generation is generally positive in the most recent periods, with positive operating cash flow and positive free cash flow in both the latest annual period and TTM (Trailing-Twelve-Months). That said, free cash flow declined meaningfully in TTM (free cash flow growth -19.3%), and cash flow performance has been uneven historically (including very large negative operating and free cash flow in 2022). Overall, current cash flow is supportive, but the recent step-down and historical volatility temper confidence.

Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	595.19M	593.82M	573.45M	665.07M	555.50M	513.70M
Gross Profit	269.63M	270.28M	254.62M	233.26M	230.62M	214.51M
EBITDA	53.93M	54.07M	71.62M	55.15M	48.35M	9.94M
Net Income	-57.82M	-55.76M	-164.90M	-14.26M	-428.96M	110.75M
Balance Sheet
Total Assets	2.07B	2.06B	2.10B	2.89B	3.72B	1.82B
Cash, Cash Equivalents and Short-Term Investments	412.05M	340.92M	462.09M	1.02B	1.57B	227.51M
Total Debt	108.92M	111.17M	70.68M	60.44M	49.23M	94.77M
Total Liabilities	359.60M	330.70M	331.07M	351.22M	352.74M	494.18M
Stockholders Equity	1.71B	1.73B	1.77B	2.53B	3.36B	1.33B
Cash Flow
Free Cash Flow	30.93M	38.32M	12.35M	-33.60M	-543.48M	97.05M
Operating Cash Flow	63.23M	72.18M	49.74M	5.83M	-466.05M	149.86M
Investing Cash Flow	-130.78M	-90.46M	224.74M	431.38M	1.47B	-146.35M
Financing Cash Flow	-7.10M	-9.59M	-659.21M	-840.46M	-62.76M	-25.91M

Azenta Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 28.18
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTA, the sentiment is Negative. The current price of 28.18 is below the 20-day moving average (MA) of 30.06, below the 50-day MA of 34.26, and below the 200-day MA of 31.80, indicating a bearish trend. The MACD of -2.20 indicates Positive momentum. The RSI at 29.10 is Positive, neither overbought nor oversold. The STOCH value of 10.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZTA.

Azenta Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BLFS	63 Neutral	$1.17B	-352.26	-5.20%	―	-18.82%	92.56%
ATRC	60 Neutral	$1.56B	-129.71	-2.40%	―	15.80%	26.94%
AZTA	55 Neutral	$1.24B	-21.28	1.69%	―	-9.49%	58.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STAA	46 Neutral	$989.86M	-10.17	-24.65%	―	-32.42%	-540.37%
QDEL	45 Neutral	$1.55B	-1.36	-46.15%	―	-3.43%	38.98%
SMTI	42 Neutral	$182.64M	-4.71	-27.19%	―	30.55%	-340.19%

Azenta Corporate Events

Azenta Shareholders Reaffirm Board, Pay Plans and Auditor

At its annual meeting on January 28, 2026, Azenta, Inc. stockholders voted to re-elect all nominated directors, signaling continued support for the company’s current board composition and governance. Investors also backed, on an advisory basis, the compensation packages for named executive officers, approved an amendment to the 2020 Equity Incentive Plan to add 2,750,000 shares for future equity grants, and ratified the appointment of PricewaterhouseCoopers LLP as Azenta’s independent auditor for the 2026 fiscal year, collectively reinforcing management’s strategic flexibility in incentivizing employees and maintaining auditor continuity for stakeholders.

The most recent analyst rating on (AZTA) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Azenta stock, see the AZTA Stock Forecast page.

Azenta divests B Medical Systems to streamline portfolio

On December 29, 2025, Azenta announced that its affiliate Azenta Germany GmbH has entered into a definitive agreement to sell the company’s Luxembourg-based B Medical Systems business, a global manufacturer and distributor of medical refrigeration devices, to THELEMA S.À R.L. for US$63 million, with the transaction expected to close on or before March 31, 2026. Management described the divestiture as a major step in simplifying Azenta’s portfolio to concentrate on its highest-impact core capabilities, with proceeds earmarked to strengthen the business and support long-term profitable value creation for shareholders, while William Blair and Taylor Wessing advised Azenta on the deal.

The most recent analyst rating on (AZTA) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on Azenta stock, see the AZTA Stock Forecast page.

Azenta Announces $250 Million Share Repurchase Program

On December 10, 2025, Azenta, Inc. announced a $250 million share repurchase program authorized by its Board of Directors, effective from December 9, 2025, to December 31, 2028. The program aims to enhance shareholder value and capitalize on stock undervaluation, with repurchases occurring through various compliant methods based on market conditions and other factors. This strategic move is part of Azenta’s capital allocation strategy, which focuses on productivity, organic growth, strategic mergers and acquisitions, and returning capital to shareholders.

The most recent analyst rating on (AZTA) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Azenta stock, see the AZTA Stock Forecast page.